Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human tumor cell heterogeneity and metastasis.

E N Spremulli, D L Dexter

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |August 1, 1983
    PubMed
    Summary

    Tumor cell heterogeneity drives metastasis, the deadliest aspect of cancer. Understanding these diverse cell populations is crucial for developing new treatments for widespread cancer.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

    International journal of oncology·2001
    Same author

    Antitumor activity and toxicity of novel nitroheterocyclic phosphoramidates.

    Journal of medicinal chemistry·2001
    Same author

    Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

    Cancer research·1997
    Same author

    Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.

    Cancer research·1994
    Same author

    Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.

    Cancer chemotherapy and pharmacology·1994
    Same author

    XB596, a promising bis-naphthalimide anti-cancer agent.

    Anti-cancer drugs·1993

    Area of Science:

    • Oncology
    • Pathology
    • Cancer Biology

    Background:

    • Tumor heterogeneity, the presence of diverse cell subpopulations within a neoplasm, has been recognized for decades.
    • This heterogeneity is now understood to play a critical role in cancer progression and treatment resistance.
    • Metastasis, driven by specific cell subpopulations, is the primary cause of cancer-related mortality.

    Purpose of the Study:

    • To review the process of metastasis.
    • To explore the relationship between tumor cell heterogeneity and metastasis.
    • To evaluate future preclinical studies for treating disseminated malignancies.

    Main Methods:

    • Literature review and synthesis of existing research on tumor heterogeneity and metastasis.
    • Exploration of intrapatient tumor heterogeneity.
    • Evaluation of preclinical study designs.

    Main Results:

    • Most tumors comprise subpopulations with varying phenotypic characteristics, including metastatic potential.
    • Metastatic cells are key drivers of patient mortality, often evading primary tumor treatments.
    • Intrapatient tumor heterogeneity presents significant challenges for effective cancer therapy.

    Conclusions:

    • Understanding tumor cell heterogeneity is essential for comprehending and combating metastasis.
    • Targeting specific metastatic subpopulations may offer novel therapeutic strategies.
    • Further preclinical research is vital for developing effective treatments for advanced cancers.

    Related Experiment Videos